In hematological malignancies such as ALL, aberrant STAT3 activation often coincides with p53 pathway attenuation, and a recent study demonstrated that pharmacological or genetic STAT3 inhibition leads to induction of the p53 response in B-ALL cells [86], demonstrating the therapeutic potential of targeting this axis. The gene discussed is TP53; the disease is acute lymphoblastic leukemia.